Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in IDH1-mutant Cholangiocarcinoma
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Tibsovo
Treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) and locally advanced or metastatic cholangiocarcinoma
View on EMATibsovo
Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy (see section 5.1). Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.
Lupus Erythematosus, Systemic
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Post Operative Pain
Locally Advanced Pancreatic Cancer
Myopia